GAGA Share Market News

[hfe_template id='11223'] [ad_1] Global brokerage firm Jefferies has reaffirmed its 'buy' rating on Polycab India but has revised its target price downwards to Rs 6,485 from the previous Rs 7,700. The brokerage firm believes that UltraTech Cement's recent foray into the cables and wires (C&W) segment is not expected to pose a significant threat to Polycab until at least 2027. Additionally, the brokerage firm’s current target price still indicates an upside potential of 40% from its closing price of Rs 4,710.65 on the BSE. Jefferies has rationalized Polycab's target Price-to-Earnings (PE) multiple by 15%, bringing it to 32x now. This adjustment comes despite the brokerage acknowledging Polycab's strong market leadership with a 25% share of the organized market. The note, however, highlights potential risks for Polycab, including increased competition and a possible slowdown in demand. However, Jefferies also points to the burgeoning opportunity in ...

[hfe_template id='11223'] [ad_1] Trump’s "America First" policies triggered a ‘quit emerging markets’ wave, hammering Indian stocks—now, China’s roaring comeback has only intensified the pain, driving the ‘Sell India, Buy China’ trade. The numbers tell the story—since October 2024, India has lost over $1 trillion in market capitalization, while China has added a staggering $2 trillion. The Hang Seng has soared 16% in a month, while the Nifty has slipped over 2%, as FIIs take renewed interest in China on the back of explosive rise of DeepSeek, relatively cheaper valuations and solid earnings growth reported by the likes of Alibaba and Lenovo. The latest Global Fund Manager Survey by BofA Securities found that investors expect EuroStoxx, Nasdaq, and Hang Seng to be the top-performing equity indices in 2025, signaling waning enthusiasm for Indian markets. “Allocations to China rebounded after falling sharply last month, while support for Indian equities, an erstwh...

[hfe_template id='11223'] [ad_1] Indicating a favorable risk-reward ratio for Oil and Natural Gas Corporation (ONGC), global brokerage firm Jefferies has reiterated its ‘buy’ rating on the stock, setting a target price of Rs 375, an upside potential of 50.5%. Following this update, the shares of ONGC surged 3.2% to an intraday high of Rs 257.15 on the BSE. The global brokerage firm also cited a strong production growth outlook over the next few fiscal years (FY25-28). The brokerage highlights ONGC's recent partnership with BP to revitalize production from its largest field as a key catalyst for growth. Jefferies has also revised its standalone earnings estimates for FY26 and FY27 upwards by 2% and 4%, respectively, reflecting increased confidence in the company's financial performance. The brokerage notes that recent regulatory actions are expected to positively impact ONGC's profitability. The report emphasizes the company's robust production growth outl...

[hfe_template id='11223'] [ad_1] The shares of LIC Housing Finance today surged 3% to an intraday high of Rs 573.65 on the BSE after the foreign brokerage firm Jefferies reaffirmed its ‘buy’ rating on the stock, albeit with a revised target price of Rs 700 (down from Rs 795 earlier), indicating a headroom of 25% growth potential. The brokerage highlighted the company's stable margins on a quarter-on-quarter (QoQ) basis while acknowledging potential headwinds from future rate cuts. A key positive noted by Jefferies is the provision reversal driven by the resolution of a wholesale account. This development has positively impacted the company's financials. The brokerage forecasts a 4% compound annual growth rate (CAGR) for earnings per share (EPS) and a return on equity (ROE) of 13-14% over the FY25-27 period. Despite the positive outlook, Jefferies suggests that a meaningful re-rating of the stock would require a pick-up in growth and a better net interest margin (...

[hfe_template id='11223'] [ad_1] 1 / 6 Brokerage Recommendations Leading brokerages have shared their latest stock recommendations, reflecting varied outlooks across key sectors for the next 12 months. Motilal Oswal has issued a "Buy" rating on Five-Star Business with a 25% upside potential, while Emkay remains bullish on Sun Pharma, projecting a robust 37% upside. Investec has upgraded UPL to a "Buy," citing operational improvements, and Jefferies continues to favor ITC with a stable outlook supported by taxation benefits. Meanwhile, JPMorgan maintains a "Neutral" stance on ONGC, noting near-term growth drivers alongside production concerns. We have collated a list of recommendations from top brokerage firms from ETNow and other sources: Agencies 2 / 6 Motilal Oswal on Five-Star Business Buy | Target Rs 930 | LTP Rs 743 | Upside 25% Motilal Oswal has given a "Buy" rating on Five-Star Business with a target price of Rs 930, indicat...

[hfe_template id='11223'] [ad_1] We have collated a list of recommendations from top brokerage firms from ETNow and other sources: Synopsis Brokerage firms remain optimistic about Dalmia Bharat, KEI Industries, and Paytm despite sectoral challenges. Jefferies targets 17% upside for Dalmia Bharat, UBS sees 42% upside for KEI, and CITI expects 17% upside for Paytm, focusing on growth and market potential. Leading brokerage firms have shared their latest views on Dalmia Bharat Ltd, KEI Industries Ltd, and Paytm, maintaining a positive outlook on these companies despite sectoral challenges and recent market dynamics.While Jefferies and UBS highlight opportunities in the cement and industrial cable sectors, respectively, CITI underscores Paytm's strategic pivot towards growth and monetization.We have collated a list of recommendations from top ETMarkets.com Jan 22, 2025, 09:39:00 AM IST Gift A Story Share member-only stories with your friends or family and help them read ...

[hfe_template id='11223'] [ad_1] Shares of Asia's oldest stock exchange, BSE Ltd, surged 4.9% on Tuesday to Rs 5,408.95 on the National Stock Exchange (NSE) after brokerage firm Jefferies upgraded its rating on the bourse to ‘hold’ from ‘underweight’ and significantly increased the target price to Rs 5,250 from Rs 3,500 earlier. The upgrade reflects Jefferies' optimism about potential earnings upgrades for BSE Ltd, despite the adverse impact of recent measures by the Securities and Exchange Board of India (Sebi) on the derivatives market. According to Jefferies, Sebi's new futures and options (F&O) rules, which mandate larger lot sizes, initially caused a sharp 70% drop in options contract volumes. However, the decline in premiums has been less severe than expected, falling by less than 10% month-to-date in January against the firm’s anticipated 25% decline, the brokerage noted. Jefferies said that while the measures have pressured discount brokers, whose...

[hfe_template id='11223'] [ad_1] Analysts at top brokerage firms have shared optimistic outlooks on key players across diverse sectors, highlighting significant growth opportunities and robust fundamentals for the upcoming year. Bernstein has initiated coverage on Swiggy with an "Outperform" rating, citing its leadership in India's convenience economy and its potential to capitalize on super-fast delivery models. Meanwhile, Jefferies remains bullish on InterGlobe Aviation (IndiGo) and Indian Hotels, emphasizing their strong market positions and promising growth trajectories. IndiGo's dominant share in domestic air travel and cost advantages, alongside Indian Hotels' consistent performance in a cyclical industry and benefits from industry tailwinds, further reinforce their appeal to investors. Here’s a summary of recommendations from top brokerage firms based on ETNow and other sources: Bernstein on Swiggy: Initiate Outperform, Target Price Rs 635 | ...

[hfe_template id='11223'] [ad_1] Global brokerage firm Jefferies has upgraded Zydus Lifesciences to a 'Buy' rating, citing the strength of the company’s US pipeline as a key driver for future growth. The brokerage raised its target price for the stock to Rs 1,450 from the previous Rs 1,210, reflecting a 30% upside potential from the previous day's closing price of Rs 1113.8 apiece on BSE. According to Jefferies, Zydus Life's US pipeline is one of the strongest in its coverage, with expectations of at least one major product launch annually, valued between $80-100 million. This robust pipeline positions the company for high-reward opportunities, despite the inherent risks associated with such non-consensus strategies. In the past three months, Zydus Life's stock has surged nearly 8%, underperforming compared to the Sensex's gain of almost 9% and the BSE Healthcare index's rise of over 19%.The recent correction in Zydus Life's stock has also...

[hfe_template id='11223'] [ad_1] New Delhi [India], August 9 (ANI): Global brokerage firm Jefferies in its latest report identifies India as a prime market for listing private equity (PE) investments, suggesting a huge pipeline for investment bankers globally. The report noted that despite the challenges faced by the private equity industry, including a liquidity squeeze and declining distributions from major firms, India remains a favorable environment for capital raising and investment opportunities. "This year a report, suggests a potentially huge pipeline for investment bankers globally but will there be the demand for all the stock and at what valuations. For now, as previously, the best market for listing PE investments remains India" said the report. The report also noted that the growing likelihood of a renewed easing cycle by the Federal Reserve could provide relief to the leveraged private equity sector. However, it also raises concerns about potentia...

[hfe_template id='11223'] [ad_1] Mumbai: ITC shares crossed the ₹500 mark for the first time on Wednesday after the budget left tobacco taxation unchanged. Analysts recommend buying the stock on any dip for a short-term return of up to 15%. After the budget, global brokerage Jefferies upgraded the stock from hold to buy and raised the target price to ₹585 from ₹435, citing ITC's clear advantage. The stock, which surged 17% in the past month compared to a 3.6% gain in the Sensex, ended at ₹494 on Wednesday, up 0.4%. "Having moved up swiftly recently, there is a possibility of consolidation or a minor dip in the next week or so, which could be an opportunity to enter near the support levels around ₹465-470," said Nagaraj Shetti, senior technical analyst at HDFC Securities. "The next upside resistance to watch is around ₹550 in the next 1-2 months." Agencies ITC has emerged from its 11-month slumber. In the past month, trading volume has steadily inc...

[hfe_template id='11223'] [ad_1] Brokerage firms such as Jefferies maintained an underperform rating on Dr Reddy’s Laboratories, Equirus recommended a Long on PI Industries, Morgan Stanley initiated coverage on Go Digit with an Equal Weight rating and Jefferies has a hold rating on Bharti Hexacom. We have collated a list of recommendations from top brokerage firms from ETNow and other sources: Jefferies on Dr Reddy’s Laboratories: Underperform | Target Rs 5010 Jefferies maintained an underperform rating on Dr Reddy’s Laboratories with a target price of Rs 5,010. Growth of acquired brands has remained stagnant in recent years and will require upfront investments. The potential impact of synergies from the acquired portfolio should start reflecting only over FY27-28. The acquisition is for GBP500m implying 2.3x sales, ~9x EV-Ebitda on CY23 numbers.Dr Reddy expects the deal to be margin accretive and remains confident of achieving 25% Ebitda margin on a consolidated basis. ...